Celerion leverages its experience, expertise and specially equipped facilities to offer a wide range of cardiovascular safety studies. Celerion is a leading provider of cardiovascular safety services in early clinical research, with over 40 years of clinical research experience, including 100s of studies to evaluate cardiovascular liability, and more than 60 Thorough QT (TQT) studies completed.
Precise evaluation of the QT interval is important in evaluating arrhythmia potential of a compound. However there are multiple off target effects of compounds which may require a more comprehensive assessment of cardiovascular safety. To address these Celerion offers a range of services, including:
Celerion provides all support services for early clinical studies including protocol development, bioanalysis, statistical analysis and report writing, giving you the ease and economy of working with one vendor for all study needs. Our flexibility enables us to efficiently conduct studies of varying size while maintaining strict data quality and patient safety standards. We have conducted a broad range of TQT studies performed involving 50 to 250 participants. We make sure that you receive fast accurate results. Our U.S. Board certified cardiologists have over 25 years of industry experience reading Holter and ECG data for the pharmaceutical industry with results that exceed industry standards.
Our industry leading highly automated ECG Core Lab reduces both time and cost for analyzing ECG data while ensuring the highest level of accuracy and precision. Celerion’s ECG Core lab senior staff has more than 15 years of experience working with regulatory authorities and assisting with study design, data analysis, and expert report writing.
Celerion 2026. All Rights Reserved. Privacy & Legal